FOXC1 Binds Enhancers and Promotes Cisplatin Resistance in Bladder Cancer

SIMPLE SUMMARY: In bladder cancer, cisplatin remains the front-line therapy, but drug resistance is common. Previously, we showed that cancer cells can spontaneously convert to an aggressive drug-resistant phenotype without mutational events. In the current work, we explored the epigenetic mechanism...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yi-Tsung, Xu, Tong, Iqbal, Maheen, Hsieh, Tien-Chan, Luo, Zhifei, Liang, Gangning, Farnham, Peggy J., Rhie, Suhn K., Goldkorn, Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996937/
https://www.ncbi.nlm.nih.gov/pubmed/35406487
http://dx.doi.org/10.3390/cancers14071717

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8996937/
https://www.ncbi.nlm.nih.gov/pubmed/35406487
http://dx.doi.org/10.3390/cancers14071717

Ejemplares similares